start friday product avail client
direct distribut list extern platform pleas reach leerink
repres would like receiv
medacorp puls call physician view stemi feasibl data
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet american associ studi liver diseas
cytopatholog obes societi zfgn protein antibodi engin summit
averag price-to-earnings large-cap revenu multipl slower-growth medic co sum part exist
franchis dcf
bottom line price concern re-emerg gilead particip hiv class
suggest unit healthcar would offer incent hiv-infect individu use
lower price gener partial gener hiv regimen instead gilead gsk recent introduc
best-in-class combin analyz list net price drug hiv class find
viabl combin treatment option still cluster net price rang
month price save payer forc patient one lower price
regimen like surprisingli modest least current price save even two-pil
solut all-gener version mylan symfi present around
save price advantag merck new combin delstrigo save
compar biktarvi dont see mani payer conclud worth troubl neg
reaction strict formulari step edit class would gener time least mean
current price new singl tablet regimen gilead biktarvi genvoya gsk
triumeq maintain may increas slowli longer term investor watch see
gsk price come dolutegravir-lamivudin two drug combin mainten treatment
hiv launch product price close list price brand dolutegravir
tivicay could disrupt hand gsk decid cannib
brand triumeq juluca instead launch list price
rang brand combin price outlook categori remain
surprisingli stabl next round patent expiri period
bottom line lower forecast amgen neulasta increas forecast
mylan fulphila neulasta biosimilar base updat launch trajectori fulphila
updat coheru recent receiv fda approv neulasta biosimilar
udenyca price target lower reiter market
perform rate price target increas reiter
outperform rate threat biosimilar neulasta final materi revenu eros
neulasta revenu contribut fulphila impact top bottom line
respect udenyca set come market begin next year second neulasta
biosimilar complic market dynam price market strategi
believ entri anoth biosimilar neulasta like trigger price reduct
neulasta fulphila price competit could get even intens spectrum
sandoz launch respect product
revenu million dilut non-gaap ep
yupelri approv expect focu shift commerci
bottom line last friday fda approv op /therav op yupelri first once-
daili nebul lama treatment patient copd overal see surpris
label continu believ yupelri differenti meaning new treatment option
moder sever copd patient drug profil reflect label distinct advantag
sunovion lonhala magnair drive sale
yupelri fda label competit see surpris
therav provid explicit guidanc price current assum net price pariti
once-daili treatment compat standard jet nebul key advantag vs lonhala
slower-than-expect launch
chang therav model
data show sign activ fall short high expect
bottom line friday societi immunotherapi cancer meet tesaro
present dose expans data amber trial combin
data show sign may re-sensit heavili pre-treat
lung cancer melanoma patient io intervent think data like view
fall short mani investor expect encourag earli find
await futur data cohort biomark result conclus
evid provid addit benefit alon view key
increment valu tsro continu show activ
least line agent less frequent dose howev even increment
de-risk rais pt see addit sign
io asset pipelin maintain op rate pt
respons rate dose level disappoint rel expect
express patient show higher respons rate etiolog clear
data cohort well biomark result pend
maintain pt see addit io asset valu
tsro host investor event et monday
highlight kol panel immuno-oncolog
bottom line host recept friday societi immunotherapi
cancer meet panel medacorp key opinion leader kol field
immuno-oncolog i/o theme discuss includ emerg new checkpoint
beyond new wave potenti i/o combin agent evolv addit
mechan target cancer immun cycl includ antigen present prime activ
cancer cell kill aim address topic addit kol gener outlook
futur i/o landscap panel discuss format
encourag enoblituzumab updat sophia
blend discount sale multipl analysi dcf w/ discount rate termin growth rate
bottom line sever present societi immunotherapi cancer
past weekend highlight updat phase dose-escal solid tumor studi
enoblituzumab plu pembrolizumab overal view updat
encourag although larg consist data previous disclos abstract updat
compani recent earn call like exceed low investor expect head
event howev enoblituzumab data appear encourag investor like remain
cautiou program given past disappoint emerg immuno-oncolog io space
addit investor cautiou ahead top-lin data readout phase sophia
studi evalu margetuximab metastat breast cancer expect host
panel featur two medacorp key opinion leader kol link kol indic
enoblituzumab combin worth pursu base improv vs would
expect monotherapi still risk associ earli stage io combin
data epacadostat ido experi offer exampl addit remain uncertainti
associ biolog also provid clariti path forward enoblituzumab
develop guid initi follow-on studi enoblituzumab combin
partner mp patient squamou cell carcinoma
head neck scchn non-smal cell lung cancer nsclc base signal activ observ
set updat model reflect develop focu enoblituzumab
increas probabl success scchn nsclc previous remov
opportun melanoma urotheli cancer pt remain reiter op
revenu mm ep
ny-eso updat larg in-lin updat may
bottom line adap present updat societi immunotherapi cancer
ny-eso tcr partner gsk pilot studi myxoid/round cell liposarcoma mrcl overal
updat larg consist data previous disclos adap earn call data
previous disclos abstract lesson ny-eso tcr program import
term platform valid proprietari program ultim key valu
driver adap view upcom clinic updat studi critic
valid adap platform thesi adap recent guid updat cohort
studi financi result may disappoint investor
hope see data investor hope data patient dose cohort
cell optim precondit regimen achiev durabl respons vs data cohort
achiev respons disappoint investor esmo recal adap
clinical-stag biotechnolog compani pioneer develop t-cell-bas immunotherapi
solid tumor view transform cell therapi space success adap
remain leader potenti disrupt cell receptor tcr field view execut key
adap stori natur consequ adap leadership posit rel new tcr field
view upcom clinic updat import valid adap platform link reiter op
present larg in-lin data previous disclos abstract
next key catalyst adap updat tcr program
financi result may
monalizumab updat larg in-lin lumox launch
bottom line updat data present societi immunotherapi cancer
iph phase ii studi evalu monalizumab wholli own astrazeneca
azn combin cetuximab previous treat recurr metastat squamou cell
carcinoma head neck r/m scchn new biomark analys present howev
efficaci data consist data previous disclos european societi medic
oncolog esmo confer octob data previous disclos abstract
recal iph recent announc expand collabor agreement azn broadli restructur
compani pipelin shift strateg focu toward rare hematolog malign iph
own full us eu commerci right fda-approv lumox moxetumomab pasudotox-
tdfk lumox immunotoxin approv fda septemb
hairi cell leukemia hcl estim market opportun us addit
lumox iph maintain intrigu early-stag pipelin includ wholli own anti-
current phase develop cutan t-cell lymphoma ctcl overal continu
view iph uniqu posit player treat rare hematolog malign differenti
pipelin focus innat immun system reiter op
data cutoff efficaci readout esmo earli biomark analys predict respons
next key catalyst iph full us commerci launch lumox
present investor/analyst event ind submiss
bottom line societi immunotherapi cancer meet present
intrigu preclin data first immuno-oncolog io program held
investor analyst event provid overview io develop plan base
present preclin data present variou confer date link link link
appreci proprietari platform continu demonstr broad util includ
indic rare metabol diseas current clinic phenylketonuria
urea cycl disord and/or hepat encephalopathi believ could add
valu io solid tumor compani leverag bacteria innat properti stimul immun
respons could amplifi genet engin technolog look forward
ind file reiter outperform
dual innat immun activ aim treat io diseas
shown posit dose-depend anti-tumor activ anim
plan ind submiss potenti upsid driver current valuat
live aha stemi feasibl modest trend toward reduc infarct size
bottom line current attend aha american heart associ annual meet
chicago -- one largest cardiolog confer stemi feasibl data
patient present today dr navin kapur part late-break clinic trial session
expect unload ventricl impella cp minut reperfus
increas infarct size day demonstr higher rate macc major advers cardiovascular
cerebrovascular event vs unload impella cp follow immedi reperfus fact
unload minut impella cp show numer trend reduct infarct size --
infarct size/tot left ventricular lv mass vs immedi reperfus
arm -- absolut reduct notabl patient larger st-elev
minut unload arm demonstr statist signific reduct infarct size
probabl encourag datapoint present us believ
addit posit signal seen recent preclin anim studi share
run last day -- recent low -- think investor like focu
encourag trend infarct size share could move modestli higher data
ultim advanc pivot studi compani expect initi next cy
stemi -- success -- could ultim doubl exist total address market
today cardiogen shock high-risk pci patient estim still
valu stemi current reflect share
host confer call discuss result tomorrow estimate dial-in
feasibl studi meet primari endpoint move pivot studi
discuss acknowledg feasibl note need standard control
stemi indic repres still anoth upsid fulli reflect stemi
athn reportedli purchas outcom given
bottom line accord reuter athn agre sell cash elliott
manag verita capit share see link believ report deal
athn good result athn sharehold given disappoint steadi declin
busi view without deal athn would like trade per share
athn reportedli purchas
link reuter articl link
link recent earn recap link
verita elliot report acquir athn
bottom line reuter report verita elliot manag announc
acquir athn around repres premium friday close
valuat consensu ebitda link previous note
believ acquisit make strateg sens verita could combin athn recent
acquir payment integr pi asset cotiviti/verscend cotiv marri cotiv vast payor
data asset athn provid asset give combin compani broad view
healthcar payment landscap link new compani could effect compet
diversifi healthcar vendor vertic integr mco
unh/op verita activ healthcar space acquir verscend
cotiv recent pay forward ebitda respect link verita also recent
acquir virenc health technolog former ge healthcar value-bas solut group
continu believ data access becom increasingli import payor provid becom
integr move system valu base care see anti-trust issu
reuter report come day bloomberg report verita elliot close ink
verita elliot decid combin athn cotv athn could match cotiv payor data asset
much covet provid data asset give compani wide-angl view healthcar ecosystem
cotiv also nascent provider-focus solut call rowdmap athn may prove synergist
rowdmap risk-readi platform
 methodolog ev ebitda multipl ebitda less nci
bottom line maintain op rate lower pt estim
slower near-term treatment growth less opportun cost per treatment improv
face delay de novo open lower treatment growth outlook near-
term compani proactiv address growth headwind work third-
parti contractor acceler open lower reimburs op contract
remain headwind potenti pressur payor though could
volum upsid reflect estim cost-per-treat improv mircera
calcimimet offer one-year tailwind reduc leverag ytd believ use
cash flow build-out de novo clinic mainten capital-expenditure debt paydown ebitda
less nci lower mm mm respect
revenu ebitda less nci modest miss expect ramp treatment growth de
novo expect
treatment outlook lower bp near-term due time de novo ramp
plan de novo open
lower reimburs network remain headwind though manag
posit potenti volum improv
solid medicar rate updat revenu tailwind
esa transit aranesp mircera annual benefit expect becom appar
add one year tailwind
ebitda expect low end guidanc mm due lower treatment growth
expect health plan headwind vs estim consensu mm time report
cffo yoy due time work capit settlement
lower pt
net revenu mm
miss longer delay better price
bottom line friday afternoon athn report disappoint result revenu
earn behind expect book declin y/i exclud charge-back
book would declin y/i despit weak quarter accord news
articl report bloomberg appear deal could come earli next week
after-market share athn start trade got lift news report
possibl pend deal believ deal announc next week even next month
stock could trade point risk reward profil becom far
appeal view manag hold call monday time earn
releas confer call unusu seem athn hope get
deal done prior report earn may caus postpon
earn week also unclear manag would choos report
friday afternoon call full busi day report possibl view
y/i declin book consider athn may want give potenti
suitor day consid stock reaction earn get final bid
call regardless result disappoint gross oper margin declin
sequenti appear relief sale book elliott may abl
take athn privat unclear us actual abl caus resurg
demand market well beyond meaning use largest enterpris
spoken seem migrat epic see restructur
abl correct maintain mp look forward earn call news
flow monday
market market go privat correct demand
market continu migrat away athn compet result disappoint
book declin substanti larg enterpris charge-back
network growth continu improv howev popul health continu declin
call monday pm passcod
bottom line auph releas financi result report cash/cash equival
st-invest compani view provid runway ampl
liquid fund pipelin pivot data alongsid manag solid execut
maintain optim auph opportun voclosporin lupu nephriti
npv call compani highlight earli complet enrol
ln studi tee top-line data roll nda complet meanwhil
manag guid enrol complet next month rare kidney
diseas program switch gear auph trial dri eye syndrom de compani plan
complet studi data anticip readout lastli ceo richard glickman
announc intent retir next year upon appoint suitabl successor updat
model accord auph financi result reiter op auph pt
revenu mm ep quarterli figur may sum annual total due chang share
 methodolog ep
bottom line follow analyst day mahwah nj reiter op rate
view new product cycles/shar gain opportun across compani busi
continu gener one better top-lin growth profil within large-
cap diversifi med-tech group addit senior leadership event includ panels/
discuss focus trauma/extrem neurovascular medsurg endoscopi division
strategi outlook provid high-level takeaway pt goe vs
roll valuat forward ep
bottom line report provid updat week end novemb
key product watch week note meaning chang follow market
copaxon share abl maintain share last week
watch see maintain continu grow vagifem glenmark teva
pick share amneal share compar week ago
within makena captur iqvia brand im share share
luitpold gener pick differenti sq makena continu hold
encourag updat poster reimburs tailwind zejula
eu
bottom line morn poster releas societi immunotherapi cancer
meet includ updat data tesaro garnet trial initi clinic
data citrino trial preclin data data
amber trial refractori nsclc present oral
session start afternoon separ uk reimburs bodi
issu decis morn recommend reimburs lynparza tablet broad
mainten potenti provid addit tailwind zejula sale europ
weekli iqvia formerli im script trend week end novemb
bottom line note analyz iqvia formerli im script trend week end novemb
harvoni epclusa vosevi mp mavyret mp zepati nr
hcv genvoya descovi odefsey biktarvi juluca gsk nr hiv tagrisso azn
nr lung cancer imbruvica abbv/jnj op zydelig venclexta abbv/rhhbi nr
hematolog malign ibranc nr kisqali nv nr verzenio nr breast
cancer xtandi zytiga prostat cancer cabometyx nr renal cell carcinoma
otezla celg op plaqu psoriasi psoriat arthriti cosentyx nv plaqu psoriasi
psoriat arthriti ankylos spondyl taltz plaqu psoriasi tremfya plaqu
psoriasi dupix sni nr/ op eucrisa atop dermat kevzara sny/
rheumatoid arthriti tecfidera mp multipl sclerosi breo anoro incrus trelegi
gsk/inva nr chronic obstruct pulmonari diseas nucala gsk fasenra azn
asthma praluent sny/regn repatha mp entresto nv cardiovascular diseas
trulic jardianc basaglar toujeo soliqua sni tresiba xultophi ozemp
nvo nr diabet austedo teva mp huntington contrav orex nr obes ocaliva
mp primari biliari cholang intrarosa mp dyspareunia actemra rhhbi
immuno-oncolog aimovig migrain
pleas see bodi report detail weekli iqvia script
googl snag high profil geising ceo david feinberg
bottom line wsj report david feinberg ceo geising join googl
overse healthcar initi link recal feinberg top pick run amazon-
berkshire-jpmorgan jv turn posit link believ yet anoth
exampl big tech get bigger healthcar new entrant seek disrupt much derid
ineffici healthcar system pleas see previou piec link link dr
feinberg clinic psychiatrist train vocal propon prevent care diagnost
test chronic diseas manag social determin healthcar aim reduc
pain point consum laud integr payor provid model kaiser
explor strateg option could help unlock valu
analysi discount rate termin growth rate
recap pipelin track present
dcf analysi revenu multipl dr tgr
 day takeaway strong foundat gene tx pivot ach data
of-the-part dcf discount rate pipelin termin growth rate
doptelet still launch slowli profit pt
 methodolog dcf discount rate termin valu
busi continu perform cch move regulatori stage
ev/ebitda multipl
look breakthrough year major event roxa pamrevlumab
ep
star align rais ep pt cfo
 methodolog price-to-earnings ep
oper progress continu wait laro approv
recap favor safeti orion bode pivot data
discount rate termin growth
fda final feedback nolasiban delay invest thesi intact
outperform market cap price price target methodolog dcf
cash flow use wacc
replac codi phipp ceo
solid quarter adopt momentum ramp
everyth goe wright momentum shld carri pt
sale
outlook still lever success pharma program cdx
outperform market cap price price target methodolog averag
ev/sal dcf
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
given superl clinic data present date expect fda approv
nov link note
larotrectinib loxo lead agent potent specif pan-trk tropomyosin receptor
kinas inhibitor combat basket tumor includ lung breast colon
trk biomark individu estim us
larotrectinib next-gen trk inhibitor partner bayer hold
ex-u commerci right pay loxo tier double-digit royalti ex-u sale
loxo bayer co-develop us cost profit split loxo
receiv up-front payment potenti receiv mileston payment
us ou larotrectinib
project combin larotrectinib peak probability-of-success
adjust sale us europ larotrectinib eu
submit august
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
sourc leerink research compani inform factset price prior day
pdufa revefenacin lama copd link link recent note
fda adcom joint anesthet analges drug product drug safeti
pdufa roxicodon abuse-deterr formul immediate-releas single-
fda adcom scienc advisori board circulatori system devic
fda adcom joint anesthet analges drug product drug safeti
north carolina dhh award rfp transit medicaid program manag
may texa hhsc award rfp star plu medicaid manag care program
american associ studi liver diseas zfgn
american societi cytopatholog
american heart associ link preview impella stemi
societi neuro-oncolog
american colleg allergi asthma immunolog
intern societi pediatr oncolog
radiolog societi north america
life scienc biolog engin confer
societi urolog oncolog
intern feder adipos therapeut scienc
asian pacif societi respirolog
american societi hematolog present pst
sadal studi abstract session
abstract paraxysm nocturn hemoglobinuria
american societi health-system pharmacist
intern symposium als/mnd
american societi cell biolog
american colleg neuropsychopharmacolog
manag end sell season
univers coverag
calendar event
model model akao asln auph bgne dova dplo
htgm obsv rgl recent updat pleas
contact leerink repres wish review
biopharma preview gener pain women health anti-infect
 biotech earn unlik offer much excit best
hcit distribut preview price pressur continu gener
medic suppli devic individu co preview cardio large-cap diversifi
medic suppli devic individu co preview ortho supplies/cap equipment/
payor servic posit catalyst
arql -- flash increment new data disclos abstract present
impress beta-th
-- flash abstract show strong symptom relief advanc sm import
imdz -- flash minor updat abstract market perform
-- flash abstract encourag investor focu remain forward-i
-- flash multipl present full sadal data confer outperform
-- flash data abstract still earli present
-- flash abstract highlight earli efficaci present
 disappoint ctad fade prospect ban bace market
-- flash data thin unconvinc benefit limit carrier
 ctad disclosur unlik bolster amyloid outlook market perform
